During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, GoBroad Healthcare Group, in collaboration with multiple partners, successfully hosted the “CHINA SUMMIT” in Chicago. The event attracted over 200 leading global oncology scholars and industry representatives onsite, with the online livestream reaching over 50,000 professionals. It served as a crucial bridge linking Chinese innovation with the global oncology community.

This year, the number of presentations delivered by Chinese experts at ASCO reached a record high. The “CHINA SUMMIT” featured outstanding researchers selected for oral presentations and abstracts at ASCO 2025, along with top global experts. The summit offered a powerful platform for sharing Chinese voices and promoting international collaboration in oncology research.

 

Opening Remarks and Institutional Commitment

The summit was co-chaired by Professors Jun Guo and Lin Shen from Peking University Cancer Hospital. Professor Jun Guo delivered the opening address, highlighting the significant progress and continuous innovation of Chinese pharmaceutical and biotech companies. He noted that China's role in global multi-center clinical trials is growing, and expressed his honor in sharing Chinese research achievements and practical experiences with international peers.

Mr. Xiaoyu Zheng, CEO of GoBroad Healthcare Group, welcomed all guests and emphasized that with the evolution of global clinical research paradigms, China is emerging as a key hub for early-stage drug development. As a pioneer in China’s research hospital ecosystem, GoBroad is committed to building an integrated clinical research system, empowering global pharmaceutical companies with high-quality early clinical data, and accelerating the journey of new drugs from lab to market. GoBroad’s scientific team also supports translational medicine, strategic development, and scientific evaluation of candidate drugs. Mr. Zheng expressed hopes for deeper global collaboration to push the boundaries of medical science for the benefit of patients worldwide.

 

Frontline Echoes: Recapturing ASCO Highlights

The summit brought together experts featured in ASCO 2025’s oral sessions and abstract presentations. Professors Xinan Sheng, Changsong Qi, Jing Pan, and Dongmei Ji from top Chinese institutions gave keynote speeches, recapturing ASCO 2025’s highlights. They shared groundbreaking research findings, China’s latest innovations in oncology, and insights into global trends in new drug development. These discussions collectively painted a visionary blueprint for the future of precision cancer medicine.

 

In-Depth Dialogues: Exploring China’s One-Stop Solutions

An interactive discussion session allowed for open global dialogue. Moderated by Mr. Xiaoyu Zheng, Professors Guo, Sheng, Qi, and Pan engaged in a deep discussion on “Entering China’s One-Stop Solutions.” They showcased how Chinese researchers are influencing global trial design and efficiency, and how collaboration with enterprises bridges the gap from lab to clinic. As researchers from GoBroad’s affiliated hospitals, the panelists detailed how GoBroad provides comprehensive local support for international projects, and expressed eagerness to deepen partnerships with overseas pharmaceutical companies to co-create a global innovation ecosystem in cancer research and treatment.

 

Youth Spotlight: USCACA ASCO Travel Award Ceremony

The summit featured a special “2025 USCACA ASCO Travel Award” ceremony. Dr. Panpan Zhang and Dr. Haoxin Peng from Peking University Cancer Hospital received the award, which honors young Chinese scholars who made outstanding contributions in translational or clinical cancer research at ASCO 2025.

 

Closing Remarks and Future Outlook

Professor Lin Shen delivered the closing remarks, summarizing the summit’s highlights and envisioning the future landscape of global oncology drug development. He encouraged more young Chinese researchers to become bridges for international exchange and congratulated everyone on the summit’s successful conclusion.

At ASCO 2025 and the “CHINA SUMMIT,” GoBroad Healthcare’s management and research teams showcased their capabilities and engaged in meaningful exchanges with global enterprises, research institutions, and industry experts. GoBroad’s one-stop IIT (Investigator-Initiated Trial) experience for overseas enterprises garnered wide attention. Moving forward, Gaobo Healthcare Group will continue working with global partners to advance high-quality oncology drug development. Through innovative technologies and its research hospital platform, Gaobo aims to enhance clinical trial efficiency and help bring more breakthrough therapies to patients around the world.

 

Yury, a 44-year-old melanoma patient from Greece, had undergone years of systemic treatment following his diagnosis of advanced cutaneous melanoma. He received surgery, monoclonal antibody therapy, radiotherapy, and two different immune-combination regimens. Despite these extensive efforts, his disease continued to progress. By May 2025, imaging showed further spread to the liver, peritoneum, hilar region, and peripancreatic areas. Genetic testing revealed an NRAS Q61R mutation, a subtype known to respond poorly to conventional therapies, greatly limiting subsequent treatment options.

After multiple lines of therapy had failed, Yury came to GoBroad Healthcare Group seeking new possibilities. Professor Jun Guo and his team conducted a comprehensive assessment of his condition, treatment history, and molecular profile. Based on this evaluation, they designed a more targeted, personalized treatment plan built around Tunlametinib combined with immunotherapy, aiming to regain disease control by inhibiting the NRAS-MEK pathway.

Just six weeks after treatment initiation, his imaging results showed an encouraging shift. His overall tumor metabolic activity decreased dramatically, several previously active lesions became metabolically inactive, and no new lesions appeared—indicating a partial response.

For a patient with NRAS-mutant melanoma who had already exhausted several immunotherapy options, this represented a highly valuable therapeutic outcome. Yury shared that the confidence he had gradually lost during years of treatment was rekindled at GoBroad, and this therapy restored his belief that his disease could once again become manageable.

Seeking more suitable treatment options, Mr. Alexander, a melanoma patient from Russia, traveled abroad and arrived at GoBroad Healthcare Group. He was evaluated and treated by Professor Jun Guo—Discipline Leader in melanoma, sarcoma, and genitourinary oncology, and one of China’s leading authorities in these fields.

After a comprehensive assessment, Professor Guo developed a personalized treatment plan for Mr. Alexander, which included the use of Tunlametinib, a drug currently approved and available only in China. While this option renewed his sense of hope, he remained concerned about potential side effects.

To support him, the GoBroad patient-service team arranged a peer-to-peer conversation with another Russian patient who had previously undergone a similar treatment at GoBroad. Their open 20-minute discussion in their shared native language provided clarity, eased anxiety, and strengthened Mr. Alexander’s confidence in the plan ahead.
Before departing, he expressed his gratitude by gifting the team a set of traditional Russian Matryoshka dolls—a warm symbol of trust and appreciation toward Professor Guo and GoBroad.

At GoBroad Healthcare Group, we are dedicated to providing global patients with reliable access to needed therapies, while delivering compassionate, culturally responsive support throughout every step of their medical journey.

WU, a 10-year-old boy from Korea, was born with a large congenital skin lesion that gradually transformed into melanoma as he grew older. The disease progressed rapidly, and within a short period, the tumor enlarged significantly and was accompanied by serious complications that disrupted daily life. Genetic testing revealed an NRAS Q61H mutation. Multiple treatments—including immunotherapy, immune-combination regimens, and targeted therapy—had been attempted but failed to control the disease. The mass continued to grow, and extensive pleural effusion developed, severely affecting his quality of life.

At this critical point, WU’s mother reached out to the team of Professor Jun Guo at GoBroad Healthcare Group, hoping to find a new treatment opportunity for her child. After evaluating his weight, tolerance, and overall condition, Professor Guo’s team designed a personalized pediatric plan: Tunlametinib at half the standard adult dose combined with immunotherapy, aiming to maintain adequate NRAS-MEK pathway inhibition while ensuring safety for a young patient.

Within just four weeks of treatment, WU experienced noticeable improvement. The previously prominent axillary mass began to shrink, associated symptoms relieved markedly, and the concerning pleural effusion resolved. Follow-up imaging confirmed the positive changes, with no new lesions detected. The overall treatment course was gentle and well-tolerated, enabling the child to continue therapy with greater ease.

For a pediatric patient facing rapid disease progression after multiple unsuccessful treatments, this swift response was profoundly meaningful. It brought renewed hope to his family. The clinical team also observed that the half-dose regimen demonstrated both strong activity and favorable safety in NRAS-mutant pediatric melanoma, offering valuable insights for future dose-optimization studies in children.